The Effect of Clinical Pharmacist-Led Comprehensive Medication Management on Chronic Disease State Goal Attainment in a Patient-Centered Medical Home.

Abstract:

BACKGROUND:Clinical pharmacy services were initiated at 7 of 11 clinics within a primary care network (PCN), which was designated as a patient-centered medical home and was affiliated with a large academic medical center in October 2014. The goal of the service was to target patients with uncontrolled chronic conditions, specifically diabetes. Patients met with a clinical pharmacist through individual clinic and telephonic appointments, in addition to usual appointments with physicians as needed. While managing patients with diabetes, many clinicians assess a patient's hemoglobin A1c (A1c), along with blood pressure and cholesterol, as indicators of disease state control and cardiovascular risk. These 3 parameters were combined into a bundled response score (BRS) in order to assess whether the addition of the clinical pharmacy service had a positive effect on patient therapeutic goal attainment rates for these areas. OBJECTIVES:To assess the effect of pharmacist-led comprehensive medication management (CMM) on therapeutic goal attainment rates for glycemic, blood pressure, and dyslipidemia outcomes in PCN patients, which was represented by a BRS based on how many therapeutic goals were met. METHODS:This retrospective study was conducted using patients seen in clinics within the PCN between October 1, 2014, and October 31, 2015. Patients were included in the intervention group if they were actively managed by a PCN pharmacist and had a diagnosis of diabetes. A control group included patients without access to a PCN pharmacist and was matched to the intervention group by baseline A1c results. Based on current clinical practice guidelines, therapeutic goals for the BRS were set as A1c ≤ 8%, blood pressure ≤ 140/90 mmHg, and prescription of a moderate- to high-intensity statin for dyslipidemia. In addition to the primary outcome, the individual components of the BRS were assessed, as well as the average number of medications used between groups. RESULTS:There were 95 patients included in the intervention group, with 132 patients included in the usual care group. Patients in the intervention group had significantly higher rates of therapeutic goal attainment for the 3 endpoints (40% vs. 12%, P < 0.001). The intervention group had statistically significantly higher improvements in the individual areas of A1c, blood pressure, and statin goal attainment. There were no significant differences in the number of medications for diabetes or antihypertensive medications used between groups at the time of study termination. CONCLUSIONS:This study demonstrated that the addition of CMM services provided by clinical pharmacists in this PCN had a positive effect on therapeutic goal attainment rates for patients with diabetes. This finding suggests that the integration of clinical pharmacists into primary care clinics could have positive effects on the clinical outcomes of diabetic patients in glycemic control, blood pressure, and statin treatment, in accordance with current guidelines. DISCLOSURES:Support for this study was provided to Wilson by the National Center for Advancing Translational Sciences, National Institutes of Health, through grant number ULI TR001860. The content of this article is solely the responsibility of the authors and does not necessarily represent the views of the National Institutes of Health. The authors have nothing additional to disclose.

authors

Prudencio J,Cutler T,Roberts S,Marin S,Wilson M

doi

10.18553/jmcp.2018.24.5.423

subject

Has Abstract

pub_date

2018-05-01 00:00:00

pages

423-429

issue

5

eissn

2376-0540

issn

2376-1032

journal_volume

24

pub_type

杂志文章
  • Emergence of BCR-ABL kinase domain mutations associated with newly diagnosed chronic myeloid leukemia: a meta-analysis of clinical trials of tyrosine kinase inhibitors.

    abstract:BACKGROUND:Tyrosine kinase inhibitors (TKIs) are a mainstay of treatment for patients suffering from chronic myeloid leukemia (CML). Testing for various mutations in the BCR-ABL gene may help predict lack of response to specific TKIs where resistance has developed. OBJECTIVE:To estimate the emergence of BCR-ABL kinase...

    journal_title:Journal of managed care & specialty pharmacy

    pub_type: 杂志文章,meta分析

    doi:10.18553/jmcp.2015.21.2.114

    authors: Ursan ID,Jiang R,Pickard EM,Lee TA,Ng D,Pickard AS

    更新日期:2015-02-01 00:00:00

  • Physician Perception of Patient Medication Adherence in a Cohort of Medicare Advantage Plans in Texas.

    abstract:BACKGROUND:Prescription medication adherence is a known health-related barrier for elderly patients, leading to insufficient disease control and negative health outcomes. The Centers for Medicare & Medicaid Services (CMS) have placed significant emphasis on medication adherence, through the Part D star measures, revolv...

    journal_title:Journal of managed care & specialty pharmacy

    pub_type: 杂志文章

    doi:10.18553/jmcp.2016.22.3.305

    authors: Winters A,Esse T,Bhansali A,Serna O,Mhatre S,Sansgiry S

    更新日期:2016-03-01 00:00:00

  • Estimated Budget Impact of Increased Use of Mirabegron, A Novel Treatment for Overactive Bladder.

    abstract:BACKGROUND:Oral pharmacological treatment for overactive bladder (OAB) consists of antimuscarinics and the beta-3 adrenergic agonist mirabegron. Antimuscarinic adverse events (AEs) such as dry mouth, constipation, and blurry vision can result in frequent treatment discontinuation rates, leaving part of the OAB populati...

    journal_title:Journal of managed care & specialty pharmacy

    pub_type: 杂志文章

    doi:10.18553/jmcp.2016.22.9.1072

    authors: Perk S,Wielage RC,Campbell NL,Klein TM,Perkins A,Posta LM,Yuran T,Klein RW,Ng DB

    更新日期:2016-09-01 00:00:00

  • AMCP Partnership Forum: Principles for Sound Pharmacy and Therapeutics (P&T) Committee Practices: What's Next?

    abstract::It has been nearly 20 years since the Academy of Managed Care Pharmacy (AMCP) and other stakeholders adopted the Principles for a Sound Formulary System. Since that time, best practices for pharmacy and therapeutics (P&T) committees have matured throughout the health care system. On March 28, 2019, AMCP convened a gro...

    journal_title:Journal of managed care & specialty pharmacy

    pub_type: 共识发展会议,杂志文章

    doi:10.18553/jmcp.2020.26.1.48

    authors:

    更新日期:2020-01-01 00:00:00

  • The Value of a Patient-Level Modeling Approach and Need for Better Reporting in Economic Evaluations of Osteoporosis.

    abstract:DISCLOSURES:No funding was involved in the writing of this letter. Outside of the submitted work, Hiligsmann has received research grants through institution from Amgen, Radius Health, UCB, and Teva/Theramex. Reginster has received research grants and/or consulting fees from Servier, Novartis, Negma, Lilly, Wyeth, Amge...

    journal_title:Journal of managed care & specialty pharmacy

    pub_type: 评论,信件

    doi:10.18553/jmcp.2020.26.3.334

    authors: Hiligsmann M,Reginster JY,Silverman S

    更新日期:2020-03-01 00:00:00

  • Impact of a clinical pharmacy program on changes in hemoglobin A1c, diabetes-related hospitalizations, and diabetes-related emergency department visits for patients with diabetes in an underserved population.

    abstract:BACKGROUND:Diabetes mellitus is associated with substantial morbidity and mortality. With the rise in prevalence of diabetes, there has been an increased need for clinical pharmacy services focused on diabetes management in ambulatory clinics. However, more data IS needed to determine the overall impact that clinical p...

    journal_title:Journal of managed care & specialty pharmacy

    pub_type: 杂志文章

    doi:10.18553/jmcp.2014.20.9.914

    authors: Chung N,Rascati K,Lopez D,Jokerst J,Garza A

    更新日期:2014-09-01 00:00:00

  • Assessment of the Level of Satisfaction and Unmet Data Needs for Specialty Drug Formulary Decisions in the United States.

    abstract:BACKGROUND:Formulary management within a limited budget is critical, especially for specialty drugs, which are used for serious medical conditions and are very expensive. Despite attempts to summarize the pertinent evidence, it is uncertain whether data needs of formulary decision makers for specialty drugs are satisfi...

    journal_title:Journal of managed care & specialty pharmacy

    pub_type: 杂志文章

    doi:10.18553/jmcp.2016.22.4.368

    authors: Choi Y,Navarro RP

    更新日期:2016-04-01 00:00:00

  • A Comparison of Health Care Resource Utilization and Costs for Patients with Allergic Rhinitis on Single-Product or Free-Combination Therapy of Intranasal Steroids and Intranasal Antihistamines.

    abstract:BACKGROUND:Allergic rhinitis (AR) is a common condition that can be treated with a number of different therapies. Treatments such as intranasal antihistamines (INAs) and intranasal steroids (INSs) are widely used by AR patients. For some allergy sufferers, a combination of therapies, specifically an INA and an INS, is ...

    journal_title:Journal of managed care & specialty pharmacy

    pub_type: 杂志文章

    doi:10.18553/jmcp.2016.22.12.1426

    authors: Harrow B,Sedaghat AR,Caldwell-Tarr A,Dufour R

    更新日期:2016-12-01 00:00:00

  • Cost-Effectiveness of a Pharmacogenetic Test to Guide Treatment for Major Depressive Disorder.

    abstract:BACKGROUND:Recent clinical trials indicate that pharmacogenetic-guided treatment of major depressive disorder (MDD) results in higher treatment response rates by genetically matching patients to medications and avoiding a trial-and-error process. OBJECTIVE:To evaluate the cost-effectiveness of a pharmacogenetic test (...

    journal_title:Journal of managed care & specialty pharmacy

    pub_type: 杂志文章

    doi:10.18553/jmcp.2018.24.8.726

    authors: Groessl EJ,Tally SR,Hillery N,Maciel A,Garces JA

    更新日期:2018-08-01 00:00:00

  • Optimizing Anti-VEGF Treatment Outcomes for Patients with Neovascular Age-Related Macular Degeneration.

    abstract:BACKGROUND:The introduction of anti-vascular endothelial growth factor (anti-VEGF) drugs to ophthalmology has revolutionized the treatment of neovascular age-related macular degeneration (nAMD). Despite this significant progress, gaps and challenges persist in the diagnosis of nAMD, initiation of treatment, and managem...

    journal_title:Journal of managed care & specialty pharmacy

    pub_type: 杂志文章,评审

    doi:10.18553/jmcp.2018.24.2-a.s3

    authors: Wykoff CC,Clark WL,Nielsen JS,Brill JV,Greene LS,Heggen CL

    更新日期:2018-02-01 00:00:00

  • Impact of Overactive Bladder Step Therapy Policies on Medication Utilization and Expenditures Among Treated Medicare Members.

    abstract:BACKGROUND:The impact of formulary management strategies on utilization and expenditures in overactive bladder (OAB) treatment has not been extensively investigated. In 2013, step therapy (ST) policies for 2 branded OAB treatments, mirabegron and fesoterodine, were removed from Humana Medicare Advantage Prescription Dr...

    journal_title:Journal of managed care & specialty pharmacy

    pub_type: 杂志文章

    doi:10.18553/jmcp.2017.23.1.27

    authors: Abbass IM,Caplan EO,Ng DB,Kristy R,Schermer CR,Bradt P,Collins JM,Chan WM,Suehs BT

    更新日期:2017-01-01 00:00:00

  • Out-of-pocket costs and oral cancer medication discontinuation in the elderly.

    abstract:BACKGROUND:Cancer is a major cause of mortality and a major contributor to health care costs in the United States. An increasing number of cancer patients are treated with oral cancer therapy. Older patients are more likely to have cancer and to be at risk for adherence problems with oral cancer drugs. As a result of s...

    journal_title:Journal of managed care & specialty pharmacy

    pub_type: 杂志文章

    doi:10.18553/jmcp.2014.20.7.669

    authors: Kaisaeng N,Harpe SE,Carroll NV

    更新日期:2014-07-01 00:00:00

  • Cost-effectiveness of Drugs to Treat Relapsed/Refractory Multiple Myeloma in the United States.

    abstract:BACKGROUND:New 3-drug regimens have been developed and approved to treat multiple myeloma (MM). The absence of direct comparative data and the high cost of treatment support the need to assess the relative clinical and economic outcomes across all approved regimens. OBJECTIVE:To evaluate the cost-effectiveness of trea...

    journal_title:Journal of managed care & specialty pharmacy

    pub_type: 杂志文章

    doi:10.18553/jmcp.2018.24.1.29

    authors: Carlson JJ,Guzauskas GF,Chapman RH,Synnott PG,Liu S,Russo ET,Pearson SD,Brouwer ED,Ollendorf DA

    更新日期:2018-01-01 00:00:00

  • Design, implementation, and first-year outcomes of a value-based drug formulary.

    abstract:BACKGROUND:Value-based insurance design attempts to align drug copayment tier with value rather than cost. Previous implementations of value-based insurance design have lowered copayments for drugs indicated for select "high value" conditions and have found modest improvements in medication adherence. However, these im...

    journal_title:Journal of managed care & specialty pharmacy

    pub_type: 杂志文章

    doi:10.18553/jmcp.2015.21.4.269

    authors: Sullivan SD,Yeung K,Vogeler C,Ramsey SD,Wong E,Murphy CO,Danielson D,Veenstra DL,Garrison LP,Burke W,Watkins JB

    更新日期:2015-04-01 00:00:00

  • Community Pharmacy Versus Mail Order: An Uneven Comparison.

    abstract:DISCLOSURES:No outside funding supported the writing of this letter. Farley has received funding from the National Community Pharmacy Association for previous research. Schondelmeyer advises the University of Minnesota Health Benefit plan on its prescription drug coverage. Urick has received a grant from Cardinal Healt...

    journal_title:Journal of managed care & specialty pharmacy

    pub_type: 评论,信件

    doi:10.18553/jmcp.2019.25.6.724

    authors:

    更新日期:2019-06-01 00:00:00

  • Measuring patient perspectives on community pharmacy quality: psychometric evaluation of a brief survey.

    abstract::BACKGROUND: Measuring patient perspectives of the quality of health care delivery is an essential component of building a patient-centered model of care, which has garnered increasing emphasis under value-based payment models. Although measurements of patient perspectives of physician practices are common, few validat...

    journal_title:Journal of managed care & specialty pharmacy

    pub_type: 杂志文章

    doi:10.18553/jmcp.2021.27.1.105

    authors: Carpenter DM,Roberts CA,Farley JF

    更新日期:2021-01-01 00:00:00

  • Health care utilization and cost associated with switching biologics within the first year of biologic treatment initiation among patients with ankylosing spondylitis.

    abstract:BACKGROUND:Costs associated with biologic switching and discontinuation can be high in chronic inflammatory diseases. Inappropriate use of medications may have cost implications for both payers and patients. Understanding of biologic utilization and switching rates is lacking among patients with ankylosing spondylitis ...

    journal_title:Journal of managed care & specialty pharmacy

    pub_type: 杂志文章

    doi:10.18553/jmcp.2020.19433

    authors: Yi E,Dai D,Piao OW,Zheng JZ,Park Y

    更新日期:2021-01-01 00:00:00

  • Evaluating Patient Preferences for Different Incentive Programs to Optimize Pharmacist-Provided Patient Care Program Enrollment.

    abstract:BACKGROUND:Employers have increased efforts to engage employees in health and wellness programs. Providing employees with incentives to participate in these programs has been shown to improve overall enrollment and engagement. One program that has had challenges with enrollment and engagement is medication therapy mana...

    journal_title:Journal of managed care & specialty pharmacy

    pub_type: 杂志文章

    doi:10.18553/jmcp.2017.23.11.1140

    authors: Tomaszewski D,Cernohous T,Vaidyanathan R

    更新日期:2017-11-01 00:00:00

  • Utilizing data consortia to monitor safety and effectiveness of biosimilars and their innovator products.

    abstract:BACKGROUND:The Biologics Price Competition and Innovation Act, introduced as part of the Affordable Care Act, directed the FDA to create an approval pathway for biologic products shown to be biosimilar or interchangeable with an FDA-approved innovator drug. These biosimilars will not be chemically identical to the refe...

    journal_title:Journal of managed care & specialty pharmacy

    pub_type: 杂志文章

    doi:10.18553/jmcp.2015.21.1.23

    authors: AMCP Task Force on Biosimilar Collective Intelligence Systems.,Baldziki M,Brown J,Chan H,Cheetham TC,Conn T,Daniel GW,Hendrickson M,Hilbrich L,Johnson A,Miller SB,Moore T,Motheral B,Priddy SA,Raebel MA,Randhawa G,Surratt

    更新日期:2015-01-01 00:00:00

  • Effect of Controlled Substance Use Management on Prescribing Patterns and Health Outcomes Among High-Risk Users.

    abstract:BACKGROUND:The misuse of prescription drugs is a serious public health problem. Although controlled substance (CS) prescribing, in particular, opioid analgesics, has recently declined, the volume of prescriptions in 2015 was still 3 times higher than in 1999. To curb the high volume of CS prescribing, a national health...

    journal_title:Journal of managed care & specialty pharmacy

    pub_type: 杂志文章

    doi:10.18553/jmcp.2019.25.3.392

    authors: Chen X,Ma Q,Barron J,DeVries A,Horn J,Agiro A

    更新日期:2019-03-01 00:00:00

  • Two-Way Clinical Messaging in a CML Specialty Pharmacy Service Model.

    abstract:BACKGROUND:Adherence to treatment is correlated with treatment success in chronic myeloid leukemia (CML). CVS Specialty explored novel methods to improve adherence in this population to ensure optimal adherence and lower the risk of unsuccessful treatment. One novel program explored involved an interactive 2-way clinic...

    journal_title:Journal of managed care & specialty pharmacy

    pub_type: 杂志文章

    doi:10.18553/jmcp.2019.25.11.1290

    authors: Sawicki C,Friend KE,Patel R,Polinski JM,Singh S

    更新日期:2019-11-01 00:00:00

  • Effect of Pharmacist-Driven Professional Continuous Glucose Monitoring in Adults with Uncontrolled Diabetes.

    abstract:BACKGROUND:Diabetes requires close monitoring to achieve optimal outcomes and avoid adverse effects. Continuous glucose monitoring (CGM) is one approach to measuring glycemia and has become more widespread with recent advances in technology; however, ideal implementation of CGM into clinical practice is unknown. CGM ca...

    journal_title:Journal of managed care & specialty pharmacy

    pub_type: 杂志文章

    doi:10.18553/jmcp.2020.26.5.600

    authors: Sherrill CH,Houpt CT,Dixon EM,Richter SJ

    更新日期:2020-05-01 00:00:00

  • Variation in Formulary Management Practices Within the Department of Veterans Affairs Health Care System.

    abstract:BACKGROUND:All Department of Veterans Affairs Medical Centers (VAMCs) operate under a single national drug formulary, yet substantial variation in prescribing and spending exists across facilities. Local management of the national formulary may differ across VAMCs and may be one cause of this variation. OBJECTIVE:To c...

    journal_title:Journal of managed care & specialty pharmacy

    pub_type: 杂志文章

    doi:10.18553/jmcp.2016.14251

    authors: Radomski TR,Good CB,Thorpe CT,Zhao X,Marcum ZA,Glassman PA,Lowe J,Mor MK,Fine MJ,Gellad WF

    更新日期:2016-02-01 00:00:00

  • Estimating the Direct Costs of Outpatient Opioid Prescriptions: A Retrospective Analysis of Data from the Rhode Island Prescription Drug Monitoring Program.

    abstract:BACKGROUND:Overuse and misuse of prescription opioids is associated with increased morbidity and mortality and places a significant cost burden on health systems. OBJECTIVE:To estimate annual statewide spending for prescription opioids in Rhode Island. METHODS:A cross-sectional study of opioids dispensed from retail ...

    journal_title:Journal of managed care & specialty pharmacy

    pub_type: 杂志文章

    doi:10.18553/jmcp.2018.24.3.214

    authors: Aroke H,Buchanan A,Wen X,Ragosta P,Koziol J,Kogut S

    更新日期:2018-03-01 00:00:00

  • Health Care Resource Utilization and Cost Before Initial Schizophrenia Diagnosis.

    abstract:BACKGROUND:The management of schizophrenia, a chronic, multifaceted mental health condition, is associated with considerable health care resource utilization (HCRU) and costs. Current evidence indicates that a high-risk and costly prodromal period, during which patients are likely symptomatic, precedes diagnosis. Bette...

    journal_title:Journal of managed care & specialty pharmacy

    pub_type: 杂志文章

    doi:10.18553/jmcp.2019.25.10.1102

    authors: Wallace A,Barron J,York W,Isenberg K,Franchino-Elder J,Sidovar M,Sand M

    更新日期:2019-10-01 00:00:00

  • Estimation of Total Costs in Pediatric and Young Adult Patients with Relapsed or Refractory Acute Lymphoblastic Leukemia Receiving Tisagenlecleucel from a U.S. Hospital's Perspective.

    abstract:BACKGROUND:Tisagenlecleucel was approved for the treatment of pediatric and young adult patients with relapsed/refractory (r/r) B-cell acute lymphoblastic leukemia (ALL) based on the pivotal ELIANA trial. OBJECTIVE:To comprehensively evaluate the total costs associated with tisagenlecleucel treatment, including costs ...

    journal_title:Journal of managed care & specialty pharmacy

    pub_type: 杂志文章

    doi:10.18553/jmcp.2020.20052

    authors: Yang H,Hao Y,Qi CZ,Chai X,Wu EQ

    更新日期:2020-08-01 00:00:00

  • A Retrospective, Longitudinal, Claims-Based Comparison of Concomitant Diagnoses Between Individuals with and Without Down Syndrome.

    abstract:BACKGROUND:Individuals with Down syndrome (DS) experience various comorbidities in excess of the prevalence seen among the non-DS population. However, the extent of the excess burden of comorbidities specifically within commercially and publicly insured DS populations aged < 21 years is not currently known. OBJECTIVES...

    journal_title:Journal of managed care & specialty pharmacy

    pub_type: 杂志文章

    doi:10.18553/jmcp.2017.23.7.761

    authors: Kong AM,Hurley D,Evans KA,Brixner D,Csoboth C,Visootsak J

    更新日期:2017-07-01 00:00:00

  • Current Procedural Terminology Codes for Medication Therapy Management in Administrative Data.

    abstract:BACKGROUND:Three pharmacist-specific Current Procedural Terminology (CPT) codes exist to facilitate medication therapy management (MTM) reimbursement (codes 99605, 99606, and 99607). However, no studies have used CPT codes in administrative claims databases to identify subjects who have received MTM services. OBJECTIV...

    journal_title:Journal of managed care & specialty pharmacy

    pub_type: 杂志文章

    doi:10.18553/jmcp.2020.26.10.1297

    authors: Axon DR,Chinthammit C,Tate J,Taylor AM,Leal S,Pickering M,Black H,Warholak T,Campbell PJ

    更新日期:2020-10-01 00:00:00

  • Health care utilization and costs by site of service for nonmetastatic breast cancer patients treated with trastuzumab.

    abstract:BACKGROUND:Adjuvant trastuzumab treatment is administered to early stage breast cancer patients in physician office (POV) or hospital outpatient (HOP) settings. OBJECTIVE:To identify treatment patterns, utilization, and costs by site of care (POV vs. HOP) of patients with adjuvant treatment of breast cancer with trast...

    journal_title:Journal of managed care & specialty pharmacy

    pub_type: 杂志文章

    doi:10.18553/jmcp.2014.20.5.485

    authors: Parthan A,Santos E,Becker L,Small A,Lalla D,Brammer M,Teitelbaum A

    更新日期:2014-05-01 00:00:00

  • Cost-Effectiveness of Pazopanib Versus Sunitinib for Renal Cancer in the United States.

    abstract::We write to comment on a recently published study by Delea et al. in the January 2015 issue of JMCP that evaluated the cost-effectiveness (CE) of sunitinib (SU) versus pazopanib (PAZ) as first-line treatment for metastatic renal cell carcinoma (mRCC) from a U.S. third-party payer perspective.1 This analysis was based ...

    journal_title:Journal of managed care & specialty pharmacy

    pub_type: 评论,信件

    doi:10.18553/jmcp.2015.21.9.834

    authors: Benedict A,Ramaswamy K,Sandin R

    更新日期:2015-09-01 00:00:00